Navigation Links
Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
Date:6/1/2011

ity, the instrument can advance research across many disease states by bringing many types of multiplexing applications to scientists. Additionally, MAGPIX allows users of legacy approaches, such as ELISA and Western Blot, to enjoy the advantages of xMAP Technology for single analyte or multiplexed testing.

"Life Technologies is pleased to be a partner in the global distribution of the MAGPIX instrument," said Peter Dansky, president of Molecular and Cell Biology at Life Technologies. "MAGPIX represents a unique platform through which Life Technologies can make its cutting-edge antibody content accessible for a broad range of protein quantitation needs in basic and clinical research."

MAGPIX saves vital time in the laboratory, produces faster, accurate, reproducible results and requires less sample input than existing legacy technologies such as ELISA and Western blot. Like other Luminex instruments, MAGPIX is versatile and flexible and can be used to analyze both nucleic acids and proteins, making it applicable in many research settings. MAGPIX is easy to install out of the box and weighs less than 40 lbs., approximately 18 kg, making it simple and affordable to ship and deploy anywhere in the world.

MAGPIX was awarded a prestigious 2011 Medical Design Excellence Award for Innovative Design and Contribution and recently received CE IVD mark in Europe.

MAGPIX is for research use only in the United States.  Not for use in diagnostic procedures.

For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix

About Luminex Corporation

Luminex Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industrie
'/>"/>

SOURCE Luminex Corporation; Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
3. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
4. Luminex Corporation to Present at UBS Global Life Sciences Conference
5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
6. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
7. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
8. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
9. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
10. Luminex Corporation Reports Third Quarter 2010 Results
11. Luminex Corporation to Present at Stephens Fall Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Oct. 16 AngioGenex Inc. (OTC,Bulletin Board: AGGX.OB) ... molecules that are potent inhibitors of the Id ... filing of this patent,constitute major milestones in the ... Dr. Richard Salvador, President and CEO, and the,former ...
... Oct. 16 When eighty-six-year-old,Keith Hora went to see ... University of Newcastle in Australia, he was told he ... been diagnosed with stage III melanoma, one,of the most ... had multiple melanoma reoccurrences in the previously treated,area of ...
Cached Medicine Technology:AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
(Date:7/9/2014)... sudden, acute episodes of low back pain are not ... pressure, wind direction and precipitation. Findings published in ... American College of Rheumatology (ACR), indicate that the risk ... speed or wind gusts, but was not clinically significant. ... nearly everyone experiences low back pain at some point ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... say, , MONDAY, July 13 (HealthDay News) -- It,s 6 a.m. ... does every morning, lets out a mix of low purr and ... me. , A new British study -- involving participants with names ... learn that this particular cry-purr combination is the most ...
... to Treat Diseases (HTDS.PK) www.htdsmedical.com - subsidiary, ... Co., Ltd for the Haemophilus influenza type b conjugate ... biggest manufacturer of Haemophilus influenza type b conjugate vaccine ... stage for Mellow Hope to be fully authorized to ...
... of cancer-prevention drug, , MONDAY, July 13 (HealthDay News) ... risk for highly aggressive prostate cancer, a new ... to determine the effect of alcohol consumption on prostate ... finasteride (Proscar, Propecia), a drug prescribed to prevent prostate ...
... Previous studies have found that postmenopausal women who ... therapy have increased their risk of developing progestin-accelerated breast ... curcumin, a popular Indian spice derived from the turmeric ... exposure to hormone replacement therapy. "Approximately 6 million ...
... , BALTIMORE,July 13 The National Federation of ... that have made outstanding contributions toward achieving the full integration of ... second annual Dr. Jacob Bolotin Awards honored eight innovators in the ... in Detroit on Wednesday, July 8. , , ...
... , Leading U.S. ... of competitors , , CINCINNATI, ... pharmacy, today announced that it will offer a 30-day supply of ... and prices below that of competitors, including Wal-Mart and Target, HealthWarehouse.com ...
Cached Medicine News:Health News:Cats Purrfect at Getting Needs Met, Study Shows 2Health News:Cats Purrfect at Getting Needs Met, Study Shows 3Health News:Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine Manufacturer in China Yunnan Walvax Biotech Co 2Health News:Heavy Drinking Linked to Aggressive Prostate Cancer 2Health News:Heavy Drinking Linked to Aggressive Prostate Cancer 3Health News:Asian spice could reduce breast cancer risk in women exposed to hormone replacement therapy 2Health News:National Federation of the Blind Awards $50,000 2Health News:HealthWarehouse.com Announces $3.50 Prescription Drug Program 2
... over 20 years of experience in ... the Life Sciences, the Freedom EVO ... possibilities for expansion according to future ... software, Freedom EVOware, each system is ...
... EVO Clinical is an open platform for clinical ... in deck sizes of 75, 100, 150 ... instrument for your laboratory space and throughput requirements. ... features to allow new applications and to evolve ...
... liquid handling system that ... of up to three ... the same worksurface. Offered ... solutions for targeted applications ...
... The AccelNet Laboratory Automation Network ... clinical chemistry systems, an automated sample ... manager to create a single, powerful ... ideal for laboratories that need a ...
Medicine Products: